Abstract Malfunction of mitochondrial complex I caused by nuclear gene mutations causes early-onset neurodegenerative diseases. Previous work using cultured fibroblasts of complex-I-deficient patients revealed elevated levels of reactive oxygen species (ROS) ] C . Together, these results provide evidence for an integral role of increased ROS levels in complex I deficiency and point to the potential therapeutic value of antioxidant treatment.
dria require a highly negative membrane potential across their inner membrane (∆ψ), which is maintained by the action of the three proton pumps (complexes I, III, and IV) of the electron transport chain. Together with F 0 /F 1 -ATPsynthase (complex V), which uses the resulting electrochemical proton gradient to generate ATP, and complex II of the electron transport chain, which oxidizes FADH 2 , these proton pumps constitute part of the oxidative phosphorylation (OXPHOS) system, which accounts for the majority of cellular ATP production.
Complex I (EC 1.6.5.3) is the largest OXPHOS complex and clinical presentations associated with its deficiency (MIM 252010) are heterogeneous ranging from severe multi-system diseases with neonatal death (e.g., Leigh Disease) to isolated myopathies [2] . Complex I consists of seven subunits encoded by the mitochondrial DNA and 38 by that of the nucleus [3] . As to the nuclear genome, disease-causing mutations have been identified in the genes of core subunits NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, and NDUFS8 [4] [5] [6] [7] [8] [9] , supernumerary subunits NDUFS4, NDUFS6, NDUFA11, and NDUFA2 [10] [11] [12] [13] , and complex I assembly factors NDUFAF2, NDUFAF1, and C6orf66 [14] [15] [16] .
Detailed knowledge of the cytopathological consequences of complex I deficiency is prerequisite to understanding the clinical presentations and their heterogeneity, and developing therapeutic strategies [17] . To gain this knowledge, we study skin fibroblasts from patients with mutations in nuclear complex I genes. We demonstrated that these mutations can be associated with a reduction in Ca 2+ content of the endoplasmic reticulum (ER Ca ; [18, 19] ). Because OXPHOS depends on the electrochemical proton gradient, the latter might be altered in patient cells, leading to a reduced supply of ATP to ER Ca 2+ -pumps, thus explaining the observed reduction in resting ER Ca . In agreement with this idea, we showed before that chronic inhibition of complex I by rotenone reduced ∆ψ and decreased ER Ca in healthy fibroblasts [20] . We furthermore showed that a reduction in ER Ca [19] . Because Bk stimulates the release of Ca 2+ from the ER into the cytosol from which Ca 2+ is taken up by mitochondria to stimulate the OXPHOS process, these data suggest that the reduction in resting ER Ca is responsible for the decrease in Bk-stimulated mitochondrial ATP production, which, in turn, results in a lower cytosolic Ca 2+ removal rate. Evidence comes from experiments with, on the one hand, an inhibitor of mitochondrial Na + -Ca 2+ exchange, which was shown to normalize both the Bkinduced increase in [ATP] M and the rate of cytosolic Ca 2+ removal in patient fibroblasts [18] , and on the other hand a mitochondrial Ca 2+ buffer, which decreased both parameters in fibroblasts of a healthy individual [21] .
Apart from alterations in intracellular Ca 2+ handling we observed elevated levels of reactive oxygen species (ROS) in fibroblasts of patients with a nuclear complex I gene defect [22, 23] . Because elevated ROS levels have been associated with a less negative ∆ψ [24, 25] , and because a less negative ∆ψ might decrease mitochondrial ATPdependent Ca 2+ uptake by the ER (see above), we here investigated the relationship between ∆ψ, elevated ROS levels and ER Ca in these patient fibroblasts.
Materials and methods

Cell lines
Fibroblasts were obtained following informed parental consent and according to the relevant Institutional Review Boards from skin biopsies of four healthy subjects and ten patients in whom an isolated complex I deficiency was confirmed in both muscle tissue and cultured fibroblasts (Table 1) . Activity measurements were performed as described previously [26] . The activity of the complex was normalized against that of cytochrome c oxidase, which was in the control range, and expressed as percentage of the lowest control (0.11 mU/mU cytochrome c oxidase; [26] ). All patients were negative with respect to mitochondrial DNA alterations previously associated with complex I deficiency. Fibroblasts were cultured in HEPES (25 mM)-buffered M199 medium (Invitrogen) supplemented with 10% (v/v) fetal calf serum, 5 mg/l Tween 20, 100 IU/ml penicillin and 100 IU/ml streptomycin.
Fluorescence imaging of ∆ψ ∆ψ was measured by digital imaging microscopy of fibroblasts loaded with tetramethyl rhodamine methyl ester (TMRM) as described in detail before [27] [Ca 2+ ] C was measured by digital imaging microscopy of fibroblasts loaded with fura-2 as previously described [18, 19, 21] . Bk, applied through the superfusion medium, evoked a transient increase in fura-2 fluorescence emission ratio. The rate of Ca 2+ removal was determined by fitting the decay phase of the transient to a mono-exponential equation as described before [18, 19, 21] .
Determination of ER Ca ER Ca was determined by digital imaging microscopy of fibroblasts loaded with fura-2 as described before [18, 19, 21] . Briefly, cells were challenged with 2′,5′-di(tert-butyl)-1,4-benzohydroquinone (BHQ; 10 µM), a specific inhibitor of the ER Ca 2+ ATPase, in the absence of external Ca 2+ (no Ca 2+ added to the extracellular medium and in the presence of 0.5 mM EGTA). Under these conditions, Ca 2+ that passively leaks out of the ER is not resequestered, resulting in a rapid increase in [Ca 2+ ] C . The peak increase in fluorescence emission ratio after treatment with BHQ was used as a measure of ER Ca .
Chemicals and statistics
Culture material and TMRM were from Invitrogen (Breda, The Netherlands). Trolox was from Fluka (Buchs, Switzerland). All other reagents were from Sigma (Zwijndrecht, the Netherlands). Values from multiple experiments were expressed as average±S.E.M and statistical significances were assessed by Student's t-test.
Results
∆ψ is reduced in complex-I-deficient patient fibroblasts Using our recently developed method for microscopic quantification of ∆ψ in cultured human skin fibroblasts [13, 27, b Determined relative to complex IV and expressed as percentage of lowest control [35] c Expressed as % of the value for control C-5120 d ER Ca , expressed as % of the value for control C-5120 [23, 25] e Expressed as % of the value for control C-5120 [27, 28] 29], we here show that ∆ψ is variably decreased in fibroblast lines of ten complex-I-deficient patients compared to four healthy individuals (Fig. 1a) . For each cell line, the average TMRM intensity per mitochondrial pixel is expressed relative to that of C-5120 healthy fibroblasts measured on the same day. Linear regression analysis revealed the absence of any correlation between ∆ψ and residual complex I activity.
∆ψ is related to cellular ROS levels and ER Ca We showed previously that cellular ROS levels are elevated to a variable extent in our whole cohort of complex-I-deficient patients (Table 1 ; [22, 23] ). Linear regression analysis revealed a negative correlation between ROS levels and ∆ψ (Fig. 1b) . We have also shown that, similar to cellular ROS levels, ER Ca is variably decreased in these patient fibroblasts (Table 1 ; [19] ). Again a significant, this time positive correlation was observed (Fig. 1c) .
Chronic Trolox treatment normalizes ∆ψ Based on the significant correlation between ROS levels and ∆ψ, as shown in Fig. 1b , we concluded that lowering of oxidant levels may restore the electrochemical proton gradient across the inner mitochondrial membrane. We previously demonstrated that chronic treatment of patient fibroblasts with Trolox, a water-soluble analogue of vitamin E, reduced ROS levels and increased the amount of fully assembled complex I [30] . Figure 2 shows that chronic Trolox (300 µM, 72 h) fully restored ∆ψ in S4-5260 and S7-5175 patient cells, which were among those displaying the largest decrease in ∆ψ (Fig. 1a) . Trolox did not affect ∆ψ in healthy fibroblasts.
Chronic Trolox treatment dose-dependently increases ER Ca A reduced ∆ψ may have severe consequences for mitochondrial energy metabolism and thus for cellular processes, such as ER Ca 2+ uptake, that depend hereupon. [19, 20, 23, 31] This prompted us to investigate the possibility that Trolox may restore ER Ca in our patient fibroblasts. Indeed, chronic Trolox (72 h) dose-dependently increased ER Ca to ∼135% of the value obtained with untreated C-5120 healthy cells in both these and S4-5260 patient fibroblasts (Fig. 3) . The halfmaximal effect was reached at ∼85 µM Trolox. In sharp contrast, acute application of Trolox (500 µM; 30 min) neither changed ER Ca in healthy (n=22 cells) nor increased it in patient (n=21 cells) fibroblasts (data not shown). The S4-5260 patient cell line was selected because it was among those with the largest decrease in ∆ψ and ER Ca . (Fig. 4b) . In S4-5260 patient cells, however, chronic Trolox dosedependently increased this parameter to the same value as in untreated healthy cells. Chronic Trolox was also without affect on the Bk-induced peak [ATP] M increase in healthy cells, whereas it normalized this parameter in patient cells (Fig. 4c ).
Chronic Trolox treatment restores aberrant
Discussion NADH:ubiquinone oxidoreductase or complex I forms a major entry point of electrons into the mitochondrial OXPHOS system and its malfunction is associated with a wide variety of clinical presentations [2] . To understand the cellular mechanisms underlying these syndromes, we study cultured skin fibroblasts of a unique cohort of patients with inherited complex I deficiency of nuclear origin [20, 31, 32] . One of our most striking findings is that the amount of fully assembled complex I is markedly decreased in patient fibroblasts, indicating that in addition to a likely decrease in intrinsic catalytic activity also its assembly and/or stability is compromised [22, 30, 32] . Other important findings include increased ROS levels and disturbances of Ca 2+ and ATP homeostasis both at rest and during stimulation [20, 31] . It is presently unknown how these changes are exactly brought about in these patient fibroblasts.
Here, we show that ∆ψ is significantly reduced in our cohort of patient fibroblast lines. At first glance, the most likely explanation would be a decrease in proton translocation. However, the OXPHOS system is most probably not working at its maximum capacity in resting fibroblasts and may, therefore, very well be able to maintain ∆ψ even when the maximum capacity of its first complex is decreased due to a lower expression and/or decreased intrinsic catalytic activity. Given the strong correlation between ROS levels and ∆ψ, i.e., the higher these levels, the less negative ∆ψ, the above finding could also be explained in that increased ROS levels induce a proton leak [33] . The relevance of the consequent ∆ψ decrease would be to try and prevent excessive ROS production. We also show that ∆ψ and ER Ca are correlated, i.e., the less negative ∆ψ, the lower ER Ca . Because ∆ψ is an important determinant for the rate of mitochondrial ATP production, this result is in agreement with our idea that fueling of ER Ca 2+ -pumps with mitochondrial ATP is reduced in resting patient fibroblasts. Importantly, our previous results argue against the idea that the reduction in ER Ca is due to increased ROS-induced Ca 2+ leak [18] .
The other major finding is that chronic Trolox normalizes ∆ψ in patient fibroblasts without affecting this parameter in healthy cells. This result is consistent with the above-described mechanism in which elevated ROS levels cause an increase in mitochondrial proton leak. Additional support comes from work demonstrating that Trolox is an efficient inhibitor of such a proton leak [34] . Normalization of ∆ψ likely restores cellular processes that are disturbed by its disease-associated reduction. Among these processes, adequate delivery of mitochondrial ATP to ER Ca 2+ -pumps is of crucial relevance. Strikingly, chronic Trolox increased ER Ca in both healthy and patient fibroblasts. Although the increase in healthy cells was unexpected in view of the lack of effect of chronic Trolox on ∆ψ, it should be noted that the increase in ER Ca observed with 100 µM Trolox was much more pronounced in patient cells, suggesting a dual mechanism involving normalization of ∆ψ (only in patient cells) and modification of a hitherto unknown process (both in healthy and patient cells). Such a dual mechanism is consistent with the idea that elevated ROS levels hamper proper fueling of ER Ca 2+ -pumps primarily by their effect on ∆ψ. Future research will reveal whether the ∆ψ-independent mechanism involves a decrease in passive Ca 2+ leak, an increase in Ca 2+ buffering capacity in the lumen of the ER and/or an increase in glycolytic ATP-dependent Ca 2+ uptake. The present result that the effect of chronic Trolox on ER Ca was paralleled by a similar effect on the Bk-induced increase in [Ca 2+ ] C is consistent with the linear relationship between both parameters in our cohort of patient fibroblast lines [19] . Similar to our finding, Trolox enhanced the bombesin-induced increase in [Ca 2+ ] C in skin fibroblasts of patients with genetic and non-genetic forms of Alzheimer's disease [35] . Although chronic Trolox markedly enhanced the Bk-induced increase in [Ca 2+ ] C in both healthy and patient fibroblasts, it did not affect the consequent increase in [Ca 2+ ] M in healthy cells, whereas it dose-dependently normalized this parameter in patient cells. Calibration of the mtAEQ signal revealed that Bk increased [Ca 2+ ] M to ∼4.5 µM [18, 19, 21] , whereas the maximum Ca 2+ concentration that can be measured is 10 µM [28] . Therefore, the results obtained suggest that the capacity of mitochondria to take up Ca is restricted to a maximum that is reached with 1 ] C transient in patient fibroblasts without affecting this parameter in healthy cells. The same observation was reached using CGP-37157 [18, 21] , whereas the opposite was observed with the mitochondrial Ca 2+ buffer Rhod-2 [21] . These results, together with the fact that the Bk-induced increase in [ATP] M is tightly correlated with the rate of cytosolic Ca 2+ removal for the whole cohort of patient fibroblasts [19] , clearly link these two processes.
In conclusion, the present results support the idea that fueling with mitochondrial ATP of cytosolic processes that are stimulated by hormone-induced increases in [Ca 2+ ] C , such as exocytotic release of neurotransmitters in nerve cells and contraction and relaxation of muscle cells, may be hampered in complex I deficiency. It is these two cell types that are among the most vulnerable in this disease [2] . However, the most important conclusion of this study is that the aberrations in Ca 2+ -stimulated mitochondrial ATP production and the consequences thereof, such as observed in complex I deficiency, can be overcome with drugs that normalize the stimulus-induced increase in [Ca 2+ ] M by either blocking mitochondrial Ca 2+ export (CGP-37157) or increasing mitochondrial Ca 2+ uptake (Trolox). It remains an important future task to translate this cellular information to clinical practice. Because patients with inborn errors of mitochondrial metabolism present with variable disease onset and a broad range of clinical symptoms, diseaseadapted or even individualized treatment strategies might be required. In this context, Trolox and CGP-37157 constitute interesting new candidates to be evaluated as treatment options.
